FACIT investment in cTRL Therapeutics focuses cell therapy R&D on Ontario for patients with cancer

October 10, 2024 – cTRL Therapeutics announced it is strengthening its research and development operations in Canada. Following an investment by FACIT, the company will establish a state-of-the-art laboratory and leverage Ontario’s world-leading cancer research network to accelerate advancement of its cancer therapeutics pipeline to benefit patients sooner.

Read More from FACIT investment in cTRL Therapeutics focuses cell therapy R&D on Ontario for patients with cancer